GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
April 25, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and...
GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses
April 17, 2023 09:00 ET
|
GeoVax, Inc.
Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate
April 06, 2023 10:00 ET
|
GeoVax, Inc.
Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax...
GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress
April 05, 2023 13:30 ET
|
GeoVax, Inc.
80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
March 30, 2023 11:00 ET
|
GeoVax, Inc.
New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update
March 23, 2023 16:00 ET
|
GeoVax, Inc.
Company Expands Ongoing Clinical Trials and theBreadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs,...
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
March 15, 2023 09:00 ET
|
GeoVax, Inc.
Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated forBest Academic/Research Team Award ATLANTA, GA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:...
GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update
March 09, 2023 09:00 ET
|
GeoVax, Inc.
Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...
GeoVax to Participate at the 35th Annual Roth Conference
March 06, 2023 09:00 ET
|
GeoVax, Inc.
Company Progress to be Discussed During Analyst-Led Fireside Chat ATLANTA, GA, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections
February 27, 2023 09:00 ET
|
GeoVax, Inc.
Data Presented Indicated Very High Levels of Immunogenicity of the Combinational Therapy ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...